BTIG Maintains Vericel(VCEL.US) With Buy Rating, Cuts Target Price to $63
Analysts Are Bullish on Top Healthcare Stocks: Vericel (VCEL), Astria Therapeutics (ATXS)
Vericel | 10-K: Annual report
Vericel Q4 Net Income, Revenue Increase; 2025 Revenue Growth Outlook Issued
Vericel | 8-K: Press Release of Vericel Corporation, “Vericel Reports Fourth Quarter and Full-Year 2024 Financial Results”
Earnings Flash (VCEL) VERICEL CORPORATION Posts Q4 Revenue $75.4M, Vs. FactSet Est of $76.5M
Express News | Vericel Corp - 2025 Financial Guidance With Total Revenue Growth of 20% to 23% Reaffirmed
Press Release: Vericel Reports Fourth Quarter and Full-Year 2024 Financial Results
Express News | Vericel Q4 Adjusted Ebitda USD 29.9 Million Vs. IBES Estimate USD 29.4 Million
Express News | Vericel Q4 EPS USD 0.38
Express News | Vericel Q4 Net Income USD 19.8 Million
Earnings Scheduled For February 27, 2025
Earnings Preview: Vericel to Report Financial Results on February 27
Vericel Corporation to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 27, 2025
Revenues Not Telling The Story For Vericel Corporation (NASDAQ:VCEL)
CCORF Maintains Vericel(VCEL.US) With Buy Rating, Raises Target Price to $67
Vericel Is Maintained at Buy by Canaccord Genuity
Optimistic Long-Term Growth Outlook for Vericel Despite Recent Setbacks
H.C. Wainwright Maintains Vericel(VCEL.US) With Buy Rating, Maintains Target Price $60
CCORF Maintains Vericel(VCEL.US) With Buy Rating, Raises Target Price to $64
Unlock the Full List